
Praveen Anand

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3582424/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia, 2022, 36, 1078-1087.	7.2	13
2	High diversity in Delta variant across countries revealed by genomeâ€wide analysis of SARSâ€CoVâ€2 beyond the Spike protein. Molecular Systems Biology, 2022, 18, e10673.	7.2	18
3	Genetic alteration of human MYH6 is mimicked by SARS-CoV-2 polyprotein: mapping viral variants of cardiac interest. Cell Death Discovery, 2022, 8, 124.	4.7	4
4	Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy. Cancer Immunology Research, 2022, 10, 1055-1068.	3.4	3
5	Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 2021, 137, 2463-2480.	1.4	35
6	Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med, 2021, 2, 965-978.e5.	4.4	40
7	Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in <i>BRAF</i> -Mutated Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6432-6444.	7.0	18
8	Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nature Cell Biology, 2021, 23, 1199-1211.	10.3	22
9	Maturity State and MCL-1 Dependence Predetermines Response to NOTCH1 Inhibition in T-ALL. Blood, 2021, 138, 3484-3484.	1.4	0
10	SARS-CoV-2 strategically mimics proteolytic activation of human ENaC. ELife, 2020, 9, .	6.0	112
11	Benchmarking evolutionary tinkering underlying human–viral molecular mimicry shows multiple host pulmonary–arterial peptides mimicked by SARS-CoV-2. Cell Death Discovery, 2020, 6, 96.	4.7	37
12	Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. ELife, 2020, 9, .	6.0	100
13	Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Seminars in Hematology, 2018, 55, 33-37.	3.4	22